乙型肝炎治愈的临床研究进展

摘要/Abstract

摘要： 乙型肝炎病毒(HBV)治愈的定义为在有限疗程后HBsAg持续消失,抑制HBV复制和病毒蛋白质的产生,并恢复对HBV的免疫应答。聚乙二醇干扰素-α(PegIFN-α)和核苷(酸)类似物(NA)是目前抑制HBV复制的常用药物,但在HBsAg转阴前停药常出现疾病复发。新疗法包括靶向于HBV生命周期中不同靶点的直接作用的抗病毒药物及抗HBV免疫的免疫调节剂等。此外,还需通过区分循环HBsAg来源、确定HBV免疫恢复,并标准化HBV RNA和乙型肝炎核心相关抗原(cccDNA转录的替代标记物)检测,从而根据患者/疾病特征和安全性,比较多种组合方案展开个体化治疗。本文就乙型肝炎治愈的临床研究进展进行综述。

关键词: 慢性乙型肝炎, 临床治愈, 抗病毒治疗, 免疫调节

宋舒瑛, 谢青, 姜绍文. 乙型肝炎治愈的临床研究进展[J]. 肝脏, 2024, 29(6): 725-730.

/ 推荐

参考文献

[1] World Health Organization. Hepatitis B[EB/OL]. (2024-09-22)[2023-07-18]. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
[2] Suk-Fong Lok A. Hepatitis B treatment: what we know now and what remains to be researched[J]. Hepatol Commun, 2018, 3(1):8-19.
[3] Jeng W J, Lok A S F. What will it take to cure hepatitis B?[J]. Hepatol Commun, 2023, 7(4):e0084.
[4] Papatheodoridis G, Triantos C, Hadziyannis E, et al. Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate[J]. J Viral Hepat, 2015, 22(12):1079-1087.
[5] Wooddell C I, Yuen M F, Chan H L, et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg[J]. Sci Transl Med, 2017, 9(409):eaan0241.
[6] Wooddell C I, Gehring A J, Yuen M F, et al. RNA interference therapy for chronic hepatitis B predicts the importance of addressing viral integration when developing novel cure strategies[J]. Viruses, 2021, 13(4):581.
[7] Montali I, Vecchi A, Rossi M, et al. Antigen load and T cell function: a challenging interaction in HBV infection[J]. Biomedicines, 2022, 10(6):1224.
[8] Lebossé F, Testoni B, Fresquet J, et al. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B[J]. J Hepatol, 2017, 66(5):897-909.
[9] Ferrando-Martinez S, Huang K, Bennett A S, et al. HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection[J]. JHEP Rep, 2019, 1(3):170-178.
[10] Ganchua S C, Paratala B, Iott C, et al. SAT397-Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells[J]. J Hepatol, 2022, 77:S851.
[11] Lok A S, Zoulim F, Dusheiko G, et al. Hepatitis B cure: From discovery to regulatory approval[J]. J Hepatol, 2017, 67(4):847-861.
[12] Yip T C, Wong G L, Chan H L, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues[J]. J Hepatol, 2019, 70(3):361-370.
[13] Yuen M F, Lim S G, Plesniak R, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection[J]. N Engl J Med, 2022, 387(21):1957-1968.
[14] Hirode G, Choi H S J, Chen C H, et al. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)[J]. Gastroenterology, 2022, 162(3):757-771.e4.
[15] Inoue T, Tanaka Y. The Role of hepatitis B core-related antigen[J]. Genes (Basel), 2019, 10(5):357.
[16] Agarwal K, Lok J, Carey I, et al. A case of HBV-induced liver failure in the REEF-2 phase Ⅱ trial: implications for finite treatment strategies in HBV 'cure'[J]. J Hepatol, 2022, 77(1):245-248.
[17] Nishio A, Bolte F J, Takeda K, et al. Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection[J]. Sci Transl Med, 2021, 13(587):eaba6322.
[18] Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA[J]. Science, 2014, 343(6176):1221-1228.
[19] Marcellin P, Bonino F, Yurdaydin C, et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients[J]. Hepatol Int, 2013, 7(1):88-97.
[20] Jeng W J, Lok A S. Should treatment indications for chronic hepatitis B be expanded?[J]. Clin Gastroenterol Hepatol, 2021, 19(10):2006-2014.
[21] Hsu Y C, Yeh M L, Wong G L, et al. Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B[J]. J Infect Dis, 2021, 224(11):1890-1899.
[22] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2):370-398.
[23] Marcellin P, Ahn S H, Ma X, et al. Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B[J]. Gastroenterology, 2016, 150(1):134-144.e10.
[24] Lim S G. HCV management in resource-constrained countries[J]. Hepatol Int, 2017, 11(3):245-254.
[25] Ren P, Li H, Huang Y, et al. A simple-to-use tool for predicting response to peginterferon in HBV DNA suppressed chronic hepatitis B patients in China[J]. Antiviral Res, 2021, 194:105163.
[26] Lampertico P, Roulot D, Wedemeyer H. Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies[J]. J Hepatol, 2022, 77(5):1422-1430.
[27] Taverniti V, Ligat G, Debing Y, et al. capsid assembly modulators as antiviral agents against HBV: molecular mechanisms and clinical perspectives[J]. J Clin Med, 2022, 11(5):1349.
[28] Gane E, Sulkowski M, Ma X L, et al. Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos (t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection[J]. J Hepatol, 2021, 75: S736.
[29] Agarwal K, Buti M, Van Bommel F, et al. Efficacyand safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: results from REEF-2 study[J]. J Hepatol, 2022, 77:S8.
[30] Bazinet M, Pantea V, Placinta G, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy[J]. Gastroenterology, 2020, 158:2180-2194.
[31] Janssen H L A, LimY S, KimH J, et al. Safety and efficacy of oral TLR8 agonist, selgantolimod, in viremic adult patients with chronic hepatitis B[J]. J Hepatol, 2021, 75: S757-758.
[32] Ma H, Lim T H, Leerapun A, et al. Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study[J]. JHEP Rep, 2021, 3:100361.
[33] Evans T, Barnes E. Phase 1b/2a study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) combined with low-dose nivolumab (LDN) in virally-suppressed patients with CHB on nucleos (t)ide analogues[J]. J Hepatol, 2022, 77:S868.
[34] Maini M K, Burton A R. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B[J]. Nat Rev Gastroenterol Hepatol, 2019, 16:662-675.
[35] Gane E, Jucov A, Dobryanska M, et al. Safety, tolerability and antiviral activity of the siRNA VIR-2218 in combination with the investigational neutralizing monoclonal antibody VIR-3434 for the treatment of chronic hepatitis B infection: preliminary results from the phase 2 MARCH trial[J]. Hepatology, 2022, 76(S1):S18.
[36] Bertoletti A. The challenges of adopting immunological biomarkers in the management of chronic HBV infection[J]. J Hepatol, 2022, 77:299-301.